PROF News & Events

Reports Q4 revenue $5.98M, consensus $10.53M. "We continued to execute well, delivering record revenues, an expanded TULSA-PRO installed base, and a stronger capital sales pipeline again in the fourth quarter - validating our belief that Q3-2025 marked an important inflection point in our business," said Arun Menawat, Profound's CEO and chairman. "Moving forward, with the strengthening of our balance sheet via the completion of our financing in December, and based on several upcoming potential catalysts, including the clinical outcomes from the Level 1 post-market CAPTAIN study, we believe that we are on the right path toward driving high double digit to low triple digit revenue growth and, ultimately, positive cash flows and net profitability."

Profound Medical announced that PRO FAMILIA Specialist Hospital in Rzeszow, Poland has completed its 500th Sonalleve Procedure. "It has been a privilege to collaborate with Dr. ozinski, Dr. Justyna Filipowska, and the entire PRO FAMILIA team to expand access to this technology," said Arun Menawat, CEO and Chairman of Profound Medical. "The U.S. commercialization of TULSA-PRO remains our primary priority, and we are pleased with its increasing adoption driven by its unique ability to effectively treat the full spectrum of prostate diseases, while minimizing side effects typically associated with surgery or radiation, such as urinary incontinence and/or erectile dysfunction."